Gibson Christopher 4

What Happened

• Christopher Gibson, a director of Pacific Biosciences of California, Inc. (PACB), was granted a derivative equity award covering 74,497 shares on 2026-06-03. The award was recorded at $0.00 per share (no cash exchange); total immediate cash value reported = $0. This is an equity grant (award/option), not a sale.

Key Details

• Transaction date: 2026-06-03; Form 4 filed 2026-06-04 (filed the next day, within normal SEC timeliness for insider reports).
• Instrument/pricing: Derivative award/option shown at $0.00 per share; 74,497 shares subject to the grant.
• Vesting: Per the filing footnote, the award vests monthly over one year on the same day of the month as the grant (or earlier at the next annual shareholders’ meeting), contingent on continued service.
• Shares owned after transaction: Not disclosed on the provided filing excerpt.
• No sale or cash proceeds were involved; this is a grant intended as compensation/retention.

Context

• This was a time-based equity award (option-style) that vests over one year—shares are not immediately transferable or sold upon grant. Such grants are common for directors as compensation/retention and do not by themselves indicate buying or selling sentiment. Future vesting could result in additional reported acquisitions if or when options are exercised or shares issued.